Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Founding precision therapy for 1q-amplified multiple myeloma

Romanos Sklavenitis-Pistofidis • 14 Sep 2019
IMW 2019
Rare Diseases Waldenström’s Macroglobulinemia

Romanos Sklavenitis-Pistofidis, MD Dana-Farber Cancer Institute, Boston, MA, discusses founding precision therapy for 1q-amplified multiple myeloma at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Romanos Sklavenitis-Pistofidis

Findings from a sequencing study evaluating tumor & immune cells in pts with MGUS, SMM & myeloma
3:14
Findings from a sequencing study evaluating tumor & immune cells in pts with MGUS, SMM & myeloma
Romanos Sklavenitis-Pistofidis • 13 Mar 2025
Single-cell RNA-sequencing of 6 million tumor and immune cells from patients with MGUS and SMM
4:18
Single-cell RNA-sequencing of 6 million tumor and immune cells from patients with MGUS and SMM
Romanos Sklavenitis-Pistofidis • 7 Dec 2024
A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WM
4:19
A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WM
Romanos Sklavenitis-Pistofidis • 18 Oct 2024
Sub-typing Waldenström's macroglobulinemia: memory B-cell subtype and plasma cell-like subtype
1:51
Sub-typing Waldenström's macroglobulinemia: memory B-cell subtype and plasma cell-like subtype
Romanos Sklavenitis-Pistofidis • 18 Oct 2024

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals